Teva Pharma Q3 Beats Market, Lifts FY24 Outlook
Teva Pharma Q3 Beats Market, Lifts FY24 Outlook; Stock Up
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Wednesday reported a loss in its third quarter, compared to prior year's profit, despite higher revenues. However, adjusted earnings and top line beat market estimates, and the firm lifted its fiscal 2024 forecast.
Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2024 Earnings Call Transcript November 6, 2024 Teva ...
In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...
As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...
Teva stock plunged Wednesday — sacrificing an earlier breakout — despite beating third-quarter expectations and raising its guidance.
Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), boosting ...
Teva Pharmaceutical Industries Ltd (TEVA) reports a 15% revenue increase and raises 2024 guidance, despite facing legal and ...
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...
On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback